T. Rancati

Breast composition and dose deposition to fat and fibroglandular tissues are associated with breast side effects after radiation therapy

A Polygenic Risk Score for Late Bladder Toxicity Following Radiotherapy for Non-Metastatic Prostate Cancer

Integrating genetic polymorphisms and clinical data to develop predictive models for skin toxicity in breast cancer radiation therapy

New rectum dose surface mapping methodology to identify rectal subregions associated with toxicities following prostate cancer radiotherapy

Dose-response mapping of bladder and rectum in prostate cancer patients undergoing radiotherapy with and without baseline toxicity correction

Integration of Dose Surface Maps and Genetic Data Identifies the Lower Posterior Rectum as a Key Region for Toxicity after Prostate Cancer Radiotherapy

Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis

Sensitivity analysis of dose-response model parameters for the bladder in prostate cancer radiotherapy

A joint physics and radiobiology DREAM team vision – Towards better response prediction models to advance radiotherapy

Optimising inter-patient image registration for image-based data mining in breast radiotherapy

Predictors of long-term adverse quality of life following breast cancer treatment – Insights from the REQUITE cohort study

Cardiac Disease in Childhood Cancer Survivors Treated With Radiation Therapy: A PENTEC Comprehensive Review

(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer

Large-scale meta–genome-wide association study reveals common genetic factors linked to radiation-induced acute toxicities across cancer types

Genome-wide association study of treatment-related toxicity two years following radiotherapy for breast cancer

Contouring variation affects estimates of normal tissue complication probability for breast fibrosis after radiotherapy

Comparison of prone and supine positioning for breast cancer radiotherapy using REQUITE data: dosimetry, acute and two years physician and patient-reported outcomes

Treatment time and circadian genotype interact to influence radiotherapy side-effects. A prospective European validation study using the REQUITE cohort

Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer

The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study

Development and Optimization of a Machine-Learning Prediction Model for Acute Desquamation After Breast Radiation Therapy in the Multicenter REQUITE Cohort

Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study)

High weekly integral dose and larger fraction size increase risk of fatigue and worsening of functional outcomes following radiotherapy for localized prostate cancer

Comparing symptom reporting by prostate cancer patients and healthcare professionals in the international multicentre REQUITE study

Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity

A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort

External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort

Genome wide association study of acute radiation toxicity and quality of life in breast cancer patients – results from the REQUITE cohort study

REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer

Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance Initiative